A2A Pharmaceuticals, Inc., 10% Owner at Biomea Fusion, Inc. (BMEA), sold 125,000 shares at $34.56 ($4.3M) on 2023-06-01, disclosed to the SEC on 2023-06-02.
Open-market sale of $4.3M BMEA by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.81 | 75,000 | $2.5M | 59.5% |
| 2 | $34.56 | 50,000 | $1.7M | 40.5% |
| Total | $34.11 avg | 125,000 | $4.3M | 100% |
| Filing → |
| BMEA | SELL | 2023-04-26 | $5.8M | — | Filing → |
| BMEA | SELL | 2023-04-06 | $6.3M | — | Filing → |
| BMEA | BUY | 2022-08-19 | $426K | — | Filing → |